文献速递免疫规划

皮内接种改善灭活SARS-CoV-2疫苗接种者的免疫应答

Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
PubMed 文献 · Vaccine · 2021-10-22

在临床试验中,接种灭活SARS-CoV-2疫苗的受试者 six 个月后抗体几乎消失。本研究通过皮内接种微量抗原来解决抗体持久性短的问题。接种后72小时内注射部位出现轻微红肿等炎症反应,第7、60和180天检测到中和抗体和ELISA(IgGs)抗S抗体水平快速升高并维持6个月。结果表明,灭活疫苗接种者存在SARS-CoV-2特异性免疫应答,皮内微量抗原接种可快速大量激活该应答,产生有效的临床保护效果。

要点

  • 灭活SARS-CoV-2疫苗接种者 six 个月后抗体几乎消失。
  • 皮内接种微量抗原后72小时内注射部位出现轻微红肿等炎症反应。
  • 接种后第7、60和180天中和抗体和ELISA(IgGs)抗S抗体水平快速升高并维持6个月。

核心结论

  • 灭活SARS-CoV-2疫苗接种者存在SARS-CoV-2特异性免疫应答,皮内微量抗原接种可快速大量激活该应答,产生有效的临床保护效果。

研究设计与样本

  • 本研究通过皮内接种微量抗原对灭活SARS-CoV-2疫苗接种者进行干预,并在接种后第7、60和180天检测抗体。

主要发现

  • 皮内接种后72小时内,受试者注射部位出现轻微红肿等炎症反应。
  • 接种后第7、60和180天,中和抗体和ELISA(IgGs)抗S抗体水平快速升高并维持6个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In clinical trials, antibodies against SARS-CoV-2 were almost eliminated in participants six months after immunization with an inactivated SARS-CoV-2 vaccine. The short duration of antibody persistence is an urgent problem. In this study, the problem was solved by intradermal inoculation with trace antigen. Within 72 h after intradermal inoculation, slight inflammatory reactions, such as redness and swelling, were observed at the inoculation site of the participants. On the 7th, 60th and 180th days after inoculation, the antibodies of the participants were detected, and it was found that the neutralizing antibody and ELISA (IgGs) anti-S antibody levels rapidly increased and were maintained for 6 months. These results indicate that there was a SARS-CoV-2-specific immune response in the participants immunized with an inactivated SARS-CoV-2 vaccine, which could be quickly and massively activated by intradermal trace antigen inoculation to produce an effective clinically protective effect.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fan S, Li D, Zhao H, et al. Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine. Vaccine. 2021. PMID: 34732278. doi:10.1016/j.vaccine.2021.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。